Susquehanna International Group
MBRX icon

Susquehanna International Group’s Moleculin Biotech MBRX Stock Holding History

Susquehanna International Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30
Closed -$10.7K – 12708
2023
Q1 		$10.7K Buy
+30
New +$13.1K ﹤0.01% 12192
2020
Q1 		– Sell
-67
Closed -$137K – 10619
2019
Q4 		$137K Buy
+67
New +$157K ﹤0.01% 8990
2019
Q3 		– Sell
-7
Closed -$20K – 10560
2019
Q2 		$20K Buy
+7
New +$19K ﹤0.01% 10006
2017
Q3 		– Sell
-12
Closed -$52K – 9292
2017
Q2 		$52K Buy
+12
New +$26.1K ﹤0.01% 8877

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PJSIMP
P.J. Schmidt Investment Management (PJS) Cedarburg, Wisconsin $643M AUM 21.84% 1-Year Est. Return

Susquehanna International Group's MBRX Position: Q2 2023 in Review

Susquehanna International Group sold out of Moleculin Biotech (MBRX) in Q2 2023, closing a stake of 30 shares — an estimated $10.7K sold.

Susquehanna International Group first reported a position in MBRX in Q2 2017 and held it in 4 quarters. The position peaked at $137K in Q4 2019. 20 funds tracked by Wall St. Rank hold MBRX as of Q2 2023.

  • Susquehanna International Group reported no remaining Moleculin Biotech position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 30 Moleculin Biotech shares in Q2 2023, an estimated $10.7K.
  • Susquehanna International Group first reported a position in Moleculin Biotech in Q2 2017 and held it in 4 quarters.
  • Susquehanna International Group's Moleculin Biotech position peaked at $137K in Q4 2019.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.